top of page

Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day

  • Apr 7
  • 1 min read

He discusses the Biogen deal, and how it is a sign of increased activity Alloy sees in their genetic medicines business. Plus, monoclonals vs multispecifics, and the state of discovery work today.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page